Artículos de revistas sobre el tema "PI3K TARGET"
Crea una cita precisa en los estilos APA, MLA, Chicago, Harvard y otros
Consulte los 50 mejores artículos de revistas para su investigación sobre el tema "PI3K TARGET".
Junto a cada fuente en la lista de referencias hay un botón "Agregar a la bibliografía". Pulsa este botón, y generaremos automáticamente la referencia bibliográfica para la obra elegida en el estilo de cita que necesites: APA, MLA, Harvard, Vancouver, Chicago, etc.
También puede descargar el texto completo de la publicación académica en formato pdf y leer en línea su resumen siempre que esté disponible en los metadatos.
Explore artículos de revistas sobre una amplia variedad de disciplinas y organice su bibliografía correctamente.
Diacovo, Thomas, Dosh Whye, Evgeni Efimenko, Jianchung Chen, Valeria Tosello, Kim De Keersmaecker, Adam Kashishian et al. "Therapeutic Utility of PI3Kγ Inhibition in Leukemogenesis and Tumor Cell Survival". Blood 120, n.º 21 (16 de noviembre de 2012): 1492. http://dx.doi.org/10.1182/blood.v120.21.1492.1492.
Texto completoBorsari, Chiara y Matthias P. Wymann. "Targeting Phosphoinositide 3-Kinase – Five Decades of Chemical Space Exploration". CHIMIA 75, n.º 12 (9 de diciembre de 2021): 1037. http://dx.doi.org/10.2533/chimia.2021.1037.
Texto completoBarberis, Laura y Emilio Hirsch. "Targeting phosphoinositide 3-kinase γ to fight inflammation and more". Thrombosis and Haemostasis 99, n.º 02 (2008): 279–85. http://dx.doi.org/10.1160/th07-10-0632.
Texto completoMiller, Michelle, Philip Thompson y Sandra Gabelli. "Structural Determinants of Isoform Selectivity in PI3K Inhibitors". Biomolecules 9, n.º 3 (26 de febrero de 2019): 82. http://dx.doi.org/10.3390/biom9030082.
Texto completoMercurio, Laura, Martina Morelli, Claudia Scarponi, Giovanni Luca Scaglione, Sabatino Pallotta, Cristina Albanesi y Stefania Madonna. "PI3Kδ Sustains Keratinocyte Hyperproliferation and Epithelial Inflammation: Implications for a Topically Druggable Target in Psoriasis". Cells 10, n.º 10 (2 de octubre de 2021): 2636. http://dx.doi.org/10.3390/cells10102636.
Texto completoLaurent, Pierre-Alexandre, Cédric Garcia, Marie-Pierre Gratacap, Bart Vanhaesebroeck, Pierre Sié, Bernard Payrastre y Anne-Dominique Terrisse. "The class I phosphoinositide 3-kinases α and β control antiphospholipid antibodies-induced platelet activation". Thrombosis and Haemostasis 115, n.º 06 (2016): 1138–46. http://dx.doi.org/10.1160/th15-08-0661.
Texto completoKuracha, Murali R., Venkatesh Govindarajan, Brian W. Loggie, Martin Tobi y Benita L. McVicker. "Pictilisib-Induced Resistance Is Mediated through FOXO1-Dependent Activation of Receptor Tyrosine Kinases in Mucinous Colorectal Adenocarcinoma Cells". International Journal of Molecular Sciences 24, n.º 15 (2 de agosto de 2023): 12331. http://dx.doi.org/10.3390/ijms241512331.
Texto completoXenou, Lydia y Evangelia A. Papakonstanti. "p110δ PI3K as a therapeutic target of solid tumours". Clinical Science 134, n.º 12 (junio de 2020): 1377–97. http://dx.doi.org/10.1042/cs20190772.
Texto completoMaffei, Angelo, Giuseppe Lembo y Daniela Carnevale. "PI3Kinases in Diabetes Mellitus and Its Related Complications". International Journal of Molecular Sciences 19, n.º 12 (18 de diciembre de 2018): 4098. http://dx.doi.org/10.3390/ijms19124098.
Texto completoChen, Shiyi, Wenkang Huang, Xiaoyu Li, Lijuan Gao y Yiping Ye. "Identifying Active Compounds and Mechanisms of Citrus changshan-Huyou Y. B. Chang against URTIs-Associated Inflammation by Network Pharmacology in Combination with Molecular Docking". Evidence-Based Complementary and Alternative Medicine 2022 (13 de julio de 2022): 1–10. http://dx.doi.org/10.1155/2022/2156157.
Texto completoHutter, Grit, Yvonne Zimmermann, Anna-Katharina Zoellner, Philip Irrgang, Oliver Weigert, Wolfgang Hiddemann y Martin Dreyling. "Combination of PI3K and PDPK1 Inhibitors Is Highly Effective in Mantle Cell Lymphoma". Blood 124, n.º 21 (6 de diciembre de 2014): 3123. http://dx.doi.org/10.1182/blood.v124.21.3123.3123.
Texto completoCourtney, Kevin D., Ryan B. Corcoran y Jeffrey A. Engelman. "The PI3K Pathway As Drug Target in Human Cancer". Journal of Clinical Oncology 28, n.º 6 (20 de febrero de 2010): 1075–83. http://dx.doi.org/10.1200/jco.2009.25.3641.
Texto completoBrosinsky, Paulin, Julia Bornbaum, Björn Warga, Lisa Schulz, Klaus-Dieter Schlüter, Alessandra Ghigo, Emilio Hirsch, Rainer Schulz, Gerhild Euler y Jacqueline Heger. "PI3K as Mediator of Apoptosis and Contractile Dysfunction in TGFβ1-Stimulated Cardiomyocytes". Biology 10, n.º 7 (16 de julio de 2021): 670. http://dx.doi.org/10.3390/biology10070670.
Texto completoMeadows, Sarah, Sorensen Rick, Yahiaoui Anella, Jia Liu, Li Li, Peng Yue, Christophe Queva y Stacey Tannheimer. "Up-Regulation of the PI3K Signaling Pathway Mediates Resistance to Idelalisib". Blood 126, n.º 23 (3 de diciembre de 2015): 3707. http://dx.doi.org/10.1182/blood.v126.23.3707.3707.
Texto completoBeck, Patrick, Kasen Reed Hutchings, Eileen Xu, Erin McDaid, Vincent Bui, Chinkal Patel, Jaime Solis et al. "PIK3CB as a potential target to regulate chemosensitivity in glioblastoma." Journal of Clinical Oncology 41, n.º 16_suppl (1 de junio de 2023): e14051-e14051. http://dx.doi.org/10.1200/jco.2023.41.16_suppl.e14051.
Texto completoMolins, Joaquim Bellmunt, Lillian Werner, Marta Guix, Elizabeth Ann Guancial, Fabio Augusto Barros Schutz, Robert O'Brien, Edward C. Stack et al. "PI3KCA mutations in advanced urothelial carcinoma: A potential therapeutic target?" Journal of Clinical Oncology 30, n.º 15_suppl (20 de mayo de 2012): 4582. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.4582.
Texto completoCao, Biyin, Jingyu Zhu, Man Wang, Yang Yu, Huixin Qi, Kunkun Han, Zubin Zhang et al. "A Novel PI3K Inhibitor Identified By a High Throughput Virtual Screen Displays Potent Activity Against Multiple Myeloma". Blood 124, n.º 21 (6 de diciembre de 2014): 4722. http://dx.doi.org/10.1182/blood.v124.21.4722.4722.
Texto completoLobo, Vítor, Ashly Rocha, Tarsila G. Castro y Maria Alice Carvalho. "Synthesis of Novel 2,9-Disubstituted-6-morpholino Purine Derivatives Assisted by Virtual Screening and Modelling of Class I PI3K Isoforms". Polymers 15, n.º 7 (29 de marzo de 2023): 1703. http://dx.doi.org/10.3390/polym15071703.
Texto completoGuenther, Andreas, Renate Burger, Wolfram Klapper, Matthias Staudinger y Martin Gramatzki. "Selective Inhibition Of The PI3K-Alpha Isoform Blocks Myeloma Cell Growth and Survival". Blood 122, n.º 21 (15 de noviembre de 2013): 5364. http://dx.doi.org/10.1182/blood.v122.21.5364.5364.
Texto completoJeong, Jae Seok, Jong Seung Kim, So Ri Kim y Yong Chul Lee. "Defining Bronchial Asthma with Phosphoinositide 3-Kinase Delta Activation: Towards Endotype-Driven Management". International Journal of Molecular Sciences 20, n.º 14 (18 de julio de 2019): 3525. http://dx.doi.org/10.3390/ijms20143525.
Texto completoChen, Yingwei, Bao-Can Wang y Yongtao Xiao. "PI3K: A potential therapeutic target for cancer". Journal of Cellular Physiology 227, n.º 7 (20 de marzo de 2012): 2818–21. http://dx.doi.org/10.1002/jcp.23038.
Texto completoRathinaswamy, Manoj K., Udit Dalwadi, Kaelin D. Fleming, Carson Adams, Jordan T. B. Stariha, Els Pardon, Minkyung Baek et al. "Structure of the phosphoinositide 3-kinase (PI3K) p110γ-p101 complex reveals molecular mechanism of GPCR activation". Science Advances 7, n.º 35 (agosto de 2021): eabj4282. http://dx.doi.org/10.1126/sciadv.abj4282.
Texto completoSmith, Stephen F., Shannon E. Collins y Pascale G. Charest. "Ras, PI3K and mTORC2 – three's a crowd?" Journal of Cell Science 133, n.º 19 (1 de octubre de 2020): jcs234930. http://dx.doi.org/10.1242/jcs.234930.
Texto completoGong, Grace Q., Jackie D. Kendall, James M. J. Dickson, Gordon W. Rewcastle, Christina M. Buchanan, William A. Denny, Peter R. Shepherd y Jack U. Flanagan. "Combining properties of different classes of PI3Kα inhibitors to understand the molecular features that confer selectivity". Biochemical Journal 474, n.º 13 (26 de junio de 2017): 2261–76. http://dx.doi.org/10.1042/bcj20161098.
Texto completoNarayanankutty, Arunaksharan. "PI3K/ Akt/ mTOR Pathway as a Therapeutic Target for Colorectal Cancer: A Review of Preclinical and Clinical Evidence". Current Drug Targets 20, n.º 12 (22 de agosto de 2019): 1217–26. http://dx.doi.org/10.2174/1389450120666190618123846.
Texto completoKang, Byung Woog y Ian Chau. "Molecular target: pan-AKT in gastric cancer". ESMO Open 5, n.º 5 (septiembre de 2020): e000728. http://dx.doi.org/10.1136/esmoopen-2020-000728.
Texto completoBheemanaboina, Rammohan R. Y. "Isoform-Selective PI3K Inhibitors for Various Diseases". Current Topics in Medicinal Chemistry 20, n.º 12 (1 de junio de 2020): 1074–92. http://dx.doi.org/10.2174/1568026620666200106141717.
Texto completoUche, Uzodinma U., Ann R. Piccirillo, Shunsuke Kataoka, Stephanie J. Grebinoski, Louise M. D’Cruz y Lawrence P. Kane. "PIK3IP1/TrIP restricts activation of T cells through inhibition of PI3K/Akt". Journal of Experimental Medicine 215, n.º 12 (14 de noviembre de 2018): 3165–79. http://dx.doi.org/10.1084/jem.20172018.
Texto completoGoncalves, Marcus D. y Azeez Farooki. "Management of Phosphatidylinositol-3-Kinase Inhibitor-Associated Hyperglycemia". Integrative Cancer Therapies 21 (enero de 2022): 153473542110731. http://dx.doi.org/10.1177/15347354211073163.
Texto completoThillai, Kiruthikah, Debashis Sarker y Claire Wells. "PAK4 as a potential therapeutic target in pancreatic ductal adenocarcinoma (PDAC)." Journal of Clinical Oncology 35, n.º 15_suppl (20 de mayo de 2017): e23139-e23139. http://dx.doi.org/10.1200/jco.2017.35.15_suppl.e23139.
Texto completoSmith, Greg C., Wee Kiat Ong, Gordon W. Rewcastle, Jackie D. Kendall, Weiping Han y Peter R. Shepherd. "Effects of acutely inhibiting PI3K isoforms and mTOR on regulation of glucose metabolism in vivo". Biochemical Journal 442, n.º 1 (27 de enero de 2012): 161–69. http://dx.doi.org/10.1042/bj20111913.
Texto completoJia, Wen-Qing, Xiao-Yan Feng, Ya-Ya Liu, Zhen-Zhen Han, Zhi Jing, Wei-Ren Xu y Xian-Chao Cheng. "Identification of Phosphoinositide-3 Kinases Delta and Gamma Dual Inhibitors Based on the p110δ/γ Crystal Structure". Letters in Drug Design & Discovery 17, n.º 6 (29 de junio de 2020): 772–86. http://dx.doi.org/10.2174/1570180816666190730163431.
Texto completoZhang, Xuewei, Masumi Ishibashi, Kazuyuki Kitatani, Shogo Shigeta, Hideki Tokunaga, Masafumi Toyoshima, Muneaki Shimada y Nobuo Yaegashi. "Potential of Tyrosine Kinase Receptor TIE-1 as Novel Therapeutic Target in High-PI3K-Expressing Ovarian Cancer". Cancers 12, n.º 6 (26 de junio de 2020): 1705. http://dx.doi.org/10.3390/cancers12061705.
Texto completoRezende, Denise C., Lorena Zaida Pacheco, Luis Arthur F. Pelloso, Maria L. Chauffaille, Marçal C. A. Silva, Elisa Kimura, Rafael L. Casaes-Rodrigues, Helena Segreto, Mihoko Yamamoto y Daniella Marcia Maranhao Bahia Kerbauy. "PI3K/AKT Pathway as a Potential Therapeutic Target In Myelodysplastic Syndrome". Blood 116, n.º 21 (19 de noviembre de 2010): 1871. http://dx.doi.org/10.1182/blood.v116.21.1871.1871.
Texto completoBlunt, Matthew D., Matthew J. Carter, Marta Larrayoz, Maria Montserrat Aguilar, Sarah Murphy, Mark Reynolds, Thomas Tipton et al. "The Dual PI3K/mTOR Inhibitor PF-04691502 Induces Substantial Apoptosis in Chronic Lymphocytic Leukemia Cells in Vitro and Prolongs Survival in the Eµ-TCL1 Mouse Model". Blood 124, n.º 21 (6 de diciembre de 2014): 832. http://dx.doi.org/10.1182/blood.v124.21.832.832.
Texto completoChen, Yu-Chen Enya, Melinda Lea Burgess, Antje Blumenthal, Sally Mapp, Peter Mollee, Devinder Gill y Nicholas Andrew Saunders. "Activation of Fc Gamma Receptor-Dependent Responses to Therapeutic Antibodies By Nurse like Cells Requires PI3Kdelta". Blood 132, Supplement 1 (29 de noviembre de 2018): 3128. http://dx.doi.org/10.1182/blood-2018-99-109719.
Texto completoBosch, Ana, Zhiqiang Li, Anna Bergamaschi, Haley Ellis, Eneda Toska, Aleix Prat, Jessica J. Tao et al. "PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor–positive breast cancer". Science Translational Medicine 7, n.º 283 (15 de abril de 2015): 283ra51. http://dx.doi.org/10.1126/scitranslmed.aaa4442.
Texto completoGiulino Roth, Lisa, Herman van Besien, Anna Rodina, Tony Taldone, Hediye Erdjument-Bromage, Matthew J. Barth, Gabriela Chiosis y Ethel Cesarman. "Targeting the Hsp90 Oncoproteome in Burkitt Lymphoma". Blood 126, n.º 23 (3 de diciembre de 2015): 592. http://dx.doi.org/10.1182/blood.v126.23.592.592.
Texto completoPopova, Nadezhda V. y Manfred Jücker. "The Role of mTOR Signaling as a Therapeutic Target in Cancer". International Journal of Molecular Sciences 22, n.º 4 (9 de febrero de 2021): 1743. http://dx.doi.org/10.3390/ijms22041743.
Texto completoDent, Paul, Steven Grant, Paul B. Fisher y David T. Curiel. "PI3K: a rational target for ovarian cancer therapy?" Cancer Biology & Therapy 8, n.º 1 (enero de 2009): 27–30. http://dx.doi.org/10.4161/cbt.8.1.7365.
Texto completoMalik, Nazma, Thomas Macartney, Annika Hornberger, Karen E. Anderson, Hannah Tovell, Alan R. Prescott y Dario R. Alessi. "Mechanism of activation of SGK3 by growth factors via the Class 1 and Class 3 PI3Ks". Biochemical Journal 475, n.º 1 (2 de enero de 2018): 117–35. http://dx.doi.org/10.1042/bcj20170650.
Texto completoMabrouk, Mohammed El, Quy N. Diep, Karim Benkirane, Rhian M. Touyz y Ernesto L. Schiffrin. "SAM68: a downstream target of angiotensin II signaling in vascular smooth muscle cells in genetic hypertension". American Journal of Physiology-Heart and Circulatory Physiology 286, n.º 5 (mayo de 2004): H1954—H1962. http://dx.doi.org/10.1152/ajpheart.00134.2003.
Texto completoYan, Zhao, Guangmei Liu, Yang Yang, Ling Chen, Ying Shang y Qian Hong. "Identifying mechanisms of Epimedii Folium against Alzheimer’s disease via a network pharmacology approach Epimedii Folium treats Alzheimer’s disease via PI3K-AKT". European Journal of Inflammation 19 (enero de 2021): 205873922110414. http://dx.doi.org/10.1177/20587392211041435.
Texto completoGao, Haotian, Zaolin Li, Kai Wang, Yuhan Zhang, Tong Wang, Fang Wang y Youjun Xu. "Design, Synthesis, and Biological Evaluation of Sulfonamide Methoxypyridine Derivatives as Novel PI3K/mTOR Dual Inhibitors". Pharmaceuticals 16, n.º 3 (20 de marzo de 2023): 461. http://dx.doi.org/10.3390/ph16030461.
Texto completoZapevalova, Maria V., Ekaterina S. Shchegravina, Irina P. Fonareva, Diana I. Salnikova, Danila V. Sorokin, Alexander M. Scherbakov, Alexander A. Maleev et al. "Synthesis, Molecular Docking, In Vitro and In Vivo Studies of Novel Dimorpholinoquinazoline-Based Potential Inhibitors of PI3K/Akt/mTOR Pathway". International Journal of Molecular Sciences 23, n.º 18 (17 de septiembre de 2022): 10854. http://dx.doi.org/10.3390/ijms231810854.
Texto completoWang, Xiaohui, Lin Zhou, Tao Zhang, Hui Chen, Xinhao Song y Feng Wang. "Effect and Mechanism of Schizandrin A in the Treatment of Liver Cancer Using Network Pharmacology, Molecular Docking, and Target Validation". Natural Product Communications 18, n.º 5 (mayo de 2023): 1934578X2311769. http://dx.doi.org/10.1177/1934578x231176916.
Texto completoLi, Jun-min, Zi-zhen Xu, Ai-hua Wang y Jiong Hu. "Activation of PI3K/Akt/mTOR Pathway in Diffuse Large B-Cell Lymphomas: Clinical Significance and Inhibitory Effect by Rituximab." Blood 114, n.º 22 (20 de noviembre de 2009): 1934. http://dx.doi.org/10.1182/blood.v114.22.1934.1934.
Texto completoCaforio, Matteo, Emmanuel de Billy, Biagio De Angelis, Stefano Iacovelli, Concetta Quintarelli, Valeria Paganelli y Valentina Folgiero. "PI3K/Akt Pathway: The Indestructible Role of a Vintage Target as a Support to the Most Recent Immunotherapeutic Approaches". Cancers 13, n.º 16 (11 de agosto de 2021): 4040. http://dx.doi.org/10.3390/cancers13164040.
Texto completoKnight, Z. A. y K. M. Shokat. "Chemically targeting the PI3K family". Biochemical Society Transactions 35, n.º 2 (20 de marzo de 2007): 245–49. http://dx.doi.org/10.1042/bst0350245.
Texto completoZuo, Ximeng, Xiaoguang Shi, Xuedan Zhang, Zhenzhou Chen, Zhenrui Yang, Xiaojuan Pan, Rui Lai y Ze Zhao. "Postoperative Ileus with the Topical Application of Tongfu Decoction Based on Network Pharmacology and Experimental Validation". Evidence-Based Complementary and Alternative Medicine 2022 (28 de marzo de 2022): 1–12. http://dx.doi.org/10.1155/2022/2347419.
Texto completo